News

News Archive 2009 ->
News Archive 2008 ->
News Archive 2007 ->
News Archive 2006 ->

Clinical Trial News

August 2010

Week 31

• PSI reached an interim enrollment milestone of 450 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI reached an interim enrollment target of 100 randomized patients in a phase III study of a novel biological agent in metastatic NSCLC.
• PSI launched a phase III study of a novel anticancer agent in patients with aggressive non-Hodgkin’s lymphoma.
• PSI met an interim enrollment objective of 150 randomized patients in a phase III study of a novel biological agent in metastatic breast cancer.

July 2010

Week 30

• PSI launched a phase III study of a novel antiemetic for the prevention of chemotherapy-induced nausea and vomiting.
• PSI initiated enrollment in a phase II study of a novel biological agent in patients with inhibitor-complicated hemophilia.
• PSI launched a phase II study of a novel agent for the treatment of patients with overactive bladder.
• PSI launched a phase II study of a novel antibiotic in patients with complicated urinary tract infections.

Week 29

• PSI initiated enrollment in a phase III study of a novel biological agent in patients with advanced breast cancer.
• PSI launched a phase III study of a novel antiemetic for the prevention of postoperative nausea and vomiting.
• PSI reached an interim enrollment milestone of 400 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.

Week 28

• PSI initiated enrollment in a phase III study of a novel biological agent in patients with Hodgkin’s lymphoma.
• PSI initiated enrollment in a phase II study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.
• PSI reached an interim enrollment objective of 50 randomized patients in a phase III study of a novel antineoplastic agent in advanced pancreatic cancer.

Week 27

• PSI reached an interim enrollment milestone of 100 randomized patients in a phase III study of a novel biological agent in metastatic breast cancer.
• PSI completed the active treatment period of a phase II study of a novel immunomodulator in patients with allergic rhinitis.
• PSI launched a phase II study of a novel immunomodulator in patients with moderately severe asthma.

June 2010

Week 26

• PSI completed a phase III study of a novel antipsychotic in patients with schizophrenia.
• PSI completed a phase II study of a novel antibiotic in patients with hospital-acquired pneumonia.
• PSI completed the active treatment period of a phase III study of a novel biological agent in patients with metastatic NSCLC.

Week 25

• PSI initiated enrollment in a phase III study of a novel biological agent in patients with severe hemophilia B.
• PSI reached an interim enrollment objective of 350 randomized patients in phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI initiated enrollment in a phase II study of a novel biological agent in patients with metastatic renal cell carcinoma.

Week 24

• PSI completed enrollment in a phase II study of a novel immunomodulator in patients with allergic rhinitis.
• PSI reached an interim enrollment objective of 50 randomized patients in a phase III study of a novel biological agent in metastatic breast cancer.
• PSI launched a phase III study of a novel biological agent in patients with hepatocellular carcinoma.
• PSI completed the active treatment period in a phase II study of a novel antiaggregant in patients with intermittent claudication.

Week 23

• PSI reached an interim enrollment target of 50 randomized patients in a phase II study of a novel immunomodulator in allergic rhinitis.
• PSI reached an interim enrollment milestone of 300 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI reached an interim enrollment milestone of 50 randomized patients in a phase III study of a novel antineoplastic agent in metastatic NSCLC.

Week 22

• PSI initiated enrollment in a phase II study of a novel immunomodulator in patients with allergic rhinitis.
• PSI met an interim enrollment milestone of 400 randomized patients in a phase III study of a novel insulin formulation in type 1 diabetes.
• PSI completed the active treatment period in a phase II study of a novel immunomodulator in patients with moderately severe asthma.

May 2010

Week 21

• PSI reached an interim enrollment objective of 250 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI initiated enrollment in a phase III rollover study of a novel biological agent in patients with metastatic renal cell carcinoma.
• PSI initiated enrollment in a phase III study of a novel biological agent in patients with metastatic breast cancer.
• PSI reached an interim enrollment milestone of 300 randomized patients in a phase III study of a novel antitumor agent in metastatic ovarian cancer.

Week 20

• PSI completed enrollment in a phase II study of a novel biological agent in patients with chemotherapy-induced anemia.
• PSI initiated enrollment in a phase III study of a novel biological agent in patients with metastatic NSCLC.
• PSI launched a phase III study of a novel biological agent in patients with chronic myelogenous leukemia.
• PSI completed a phase III study of a novel bisphosphonate in patients with osteoporosis.

Week 19

• PSI reached an interim enrollment objective of 200 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI reached an interim enrollment target of 50 randomized patients in a phase III rollover study of a novel biological agent in relapsing-remitting multiple sclerosis.
• PSI launched a phase II study of a novel antiviral in patients with chronic hepatitis C.
• PSI completed a phase II study of a novel antitumor agent in patients with metastatic NSCLC.

Week 18

• PSI completed a phase II study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.
• PSI completed a phase II study of a novel disease-modifying agent in patients with rheumatoid arthritis.
• PSI completed a phase II study of a novel antihyperglycemic in patients with type 2 diabetes.
• PSI completed a phase II study of a novel biological agent in patients with ulcerative colitis.

April 2010

Week 17

• PSI completed a phase III study of a novel antibiotic in patients with community-acquired pneumonia.
• PSI completed a phase II study of a novel antineoplastic agent in patients with chronic lymphocytic leukemia.
• PSI completed a phase III study of a novel immunomodulator in patients undergoing renal transplantation.

Week 16

• PSI reached an interim enrollment objective of 150 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI launched a phase III study of a novel biological agent in patients with gastrointestinal stromal tumors.
• PSI launched a phase I/II study of a novel anticancer agent in patients with advanced NSCLC.

Week 15

• PSI reached an interim enrollment objective of 100 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI completed enrollment in a phase III study of a novel biological agent in patients with gout.
• PSI launched a phase I/II study of a novel anticancer agent in patients with castrate-resistant prostate cancer.

Week 14

• PSI completed the active treatment period in a phase II study of a novel cytotoxic agent in patients with hormone-refractory prostate cancer.
• PSI completed the active treatment period in a phase II study of a novel cytotoxic agent in patients with metastatic colorectal cancer.
• PSI completed a phase II study of a novel antitumor agent in patients with castrate-resistant prostate cancer.

March 2010

Week 13

• PSI reached an interim enrollment objective of 50 randomized patients in a phase III study of a novel biological agent in metastatic renal cell carcinoma.
• PSI initiated recruitment in a phase III study of a novel biological agent in patients with gout.
• PSI completed the active treatment period in a phase III study of a novel cytotoxic agent in patients with metastatic breast cancer.

Week 12

• PSI completed a phase II study of a novel biological agent in patients with moderately severe asthma.
• PSI completed the active treatment period in a proof-of-concept study of a novel anti-inflammatory agent in patients with allergic rhinitis.
• PSI completed a proof-of-principle study of a novel biological agent in patients with rheumatoid arthritis.

Week 11

• PSI launched a phase III study of a novel cytotoxic agent in patients with metastatic colorectal cancer.
• PSI launched a phase II study of a novel immunomodulator in patients with allergic rhinitis.
• PSI launched a phase II study of a novel hemodynamic agent in patients with severe congestive heart failure.
• PSI launched a phase III study of a novel hormonal agent in patients with hypoparathyroidism.

Week 10

• PSI launched a phase III study of a novel biological agent in patients with hematologic malignancies.
• PSI completed enrollment in a phase III study of a novel hormonal agent in patients with hormone-sensitive prostate cancer.
• PSI completed enrollment in a phase II study of a novel biological agent in patients with metastatic colorectal cancer.
• PSI reached an interim recruitment objective of 50 randomized patients in a phase III study of a novel biological agent in acute myeloid leukemia.

Week 9

• PSI completed enrollment in a phase II study of a novel biological agent in patients with severe hemophilia A.
• PSI initiated recruitment in a proof-of-concept study of a novel cytotoxic agent in patients with advanced breast cancer.
• PSI completed the active treatment period in a phase II study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.

February 2010

Week 8

• PSI completed a phase II study of a novel cytotoxic agent in patients with metastatic NSCLC.
• PSI initiated recruitment in a phase III study of a novel biological agent in patients with relapsing-remitting multiple sclerosis.
• PSI completed a phase II study of a novel biological agent in patients with ulcerative colitis.

Week 7

• PSI reached an interim enrollment milestone of 200 randomized patients in a phase III study of a novel hormonal agent in hormone-sensitive prostate cancer.
• PSI launched a phase III study of a novel biological agent in patients with advanced NSCLC.
• PSI initiated enrollment in a proof-of-concept study of a novel biologic in patients with non-Hodgkin’s lymphoma.

Week 6

• PSI completed recruitment in phase II study of a novel immunomodulator in patients with allergic rhinitis.
• PSI launched a phase III study of a novel antineoplastic agent in patients with uterine cancer.
• PSI reached an interim enrollment target of 100 randomized patients in a phase II study of a novel biological agent in metastatic colorectal cancer.
• PSI reached an interim enrollment target of 250 randomized patients in a phase III study of a novel antineoplastic agent in patients with metastatic ovarian cancer.

Week 5

• PSI initiated patient enrollment in a phase II study of a novel immunomodulator in allergic rhinitis.
• PSI initiated launched a phase II study of a novel anticancer agent in patients with metastatic pancreatic cancer.
• PSI completed a phase II study of a novel hormonal agent in patients with receptor-positive breast cancer.

January 2010

Week 4

• PSI launched a phase III study of a novel biologic in patients with advanced breast cancer.
• PSI completed the active treatment period in a phase III study of a novel anticancer agent in patients with small-cell lung cancer.
• PSI completed enrollment in a phase III study of a novel biological agent in patients with severe hemophilia A.

Week 3

• PSI initiated recruitment in a phase III trial of a novel biologic in patients with metastatic renal cell carcinoma.
• PSI launched a phase III study of a novel biological agent in patients with multiple myeloma.
• PSI completed the active treatment period in a proof-of-concept study of a novel biological agent in patients with rheumatoid arthritis.

Week 2

• PSI completed recruitment in a phase III trial of a novel antiviral in patients with chronic hepatitis B.
• PSI completed the active treatment period in a phase II study of a novel anticancer agent with patients with hormone-refractory prostate cancer.
• PSI completed the active treatment phase in a phase II study of a novel hematopoietic agent in patients with anemia secondary to chronic kidney disease.

Week 1

• PSI completed a phase II study of a novel anticancer agent in patients with metastatic NSCLC.
• PSI initiated a phase II study of a novel biologic in patients with non-Hodgkin’s lymphoma.